ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-GARP Monoclonal Antibody PBA-0111

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by Pure Biologics.

Furthest: early phase 1, since Nov 19, 20241 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pure Biologics11 open or runningearly phase 1since Nov 19, 2024Nov 19, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2024First study: early phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT06700070 · 12 planned · United States

TargetBeta

“An afucosylated human monoclonal antibody directed against the transforming growth factor beta (TGF-beta) activator glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06700070Squamous Cell Carcinoma of Head and Neck · United StatesEarly 1RecruitingDec 202512

How it is read

Names in the registry

  • “PBA-0111”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.